[{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Israel Biotech Fund","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"||RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2020","type":"Series C Financing","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Biosight \/ Israel Biotech Fund","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Israel Biotech Fund"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Biosight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Merger","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Ayala Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Biosight","highestDevelopmentStatusID":"8","companyTruncated":"Ayala Pharmaceuticals \/ Biosight"},{"orgOrder":0,"company":"European Cooperative Group","sponsor":"Groupe Francophone","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"European Cooperative Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"European Cooperative Group \/ Groupe Francophone","highestDevelopmentStatusID":"8","companyTruncated":"European Cooperative Group \/ Groupe Francophone"},{"orgOrder":0,"company":"Groupe Francophone des Myelodysplasies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Groupe Francophone des Myelodysplasies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Groupe Francophone des Myelodysplasies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Groupe Francophone des Myelodysplasies \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"},{"orgOrder":0,"company":"Biosight","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspacytarabine","moa":"RNA | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Biosight","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosight \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosight \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Aspacytarabine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : BST-236 (aspacytarabine) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. Aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          November 22, 2022

                          Lead Product(s) : Aspacytarabine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Astarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 16, 2022

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Aspacytarabine (BST-236), is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine for the treatment of acute myeloid leukemia.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          August 01, 2022

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Phase 2b clinical trial of BST-236 (Aspacytarabine), showed a complete remission rate of 37%, of which 50% were minimal residual disease negative. Rapid complete hematological recovery was observed with a median time of 25 days for complete neutrophil r...

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          January 06, 2022

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : $50.0 million

                          July 06, 2021

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Biosight

                          Deal Size : $50.0 million

                          Deal Type : Merger

                          blank

                          06

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : The data reported to date provide compelling evidence that aspacytarabine, with a differentiated mechanism that enables high-dose chemotherapy with reduced toxicity, has the potential to transform standard of care for AML patients.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          May 11, 2021

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Groupe Francophone des Myelodysplasies

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Groupe Francophone des Myelodysplasies

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Astarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 01, 2021

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Astarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 11, 2021

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Aspacytarabine, Biosight’s lead product candidate, is a novel antimetabolite designed to provide the benefit of intensive chemotherapy while reducing the associated systemic toxicity.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : These additional proceeds will be used to advance the clinical development of Biosight’s lead asset BST-236 (aspacytarabine), currently being investigated in a multi-center Phase 2b study in the U.S.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          December 02, 2020

                          Lead Product(s) : Aspacytarabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Israel Biotech Fund

                          Deal Size : $46.0 million

                          Deal Type : Series C Financing

                          blank